MPS Industry Information
As an information service the National MPS Society includes links to the websites of the major pharmaceutical companies involved in the development and production of therapies for mucopolysaccharide and other lysosomal storage diseases.
These links are provided as an information service only. We applaud the effort of companies to develop therapies for these devastating diseases, and we will work co-operatively with them and with medical professionals to ensure that effective therapies are made available to affected individuals, as soon as they are available. However we are unable to give endorsement to the products of any particular company.
These major companies are involved in developing enzyme replacement therapies and/or gene therapy products, for mucopolysaccharide and other lysosomal storage diseases, and whose sites are known to the National MPS Society. Other companies may also be involved in development work on such therapies, and if we are notified of their site details, links will also be added.
BioMarin Parmaceutical develops enzyme therapies for serious, life-threatening diseases and conditions. We are committed to improving the lives of patients by developing novel enzyme therapies for currently unmet medical needs.
Genzyme Corporation is a biotechnology company that develops and markets innovative products and services for unmet medical needs
Shire Pharmaceutical, formerly known as Transkaryotic Therapies, Inc. (TKT) is a biopharmaceutical company located in Cambridge, MA, with a major focus on developing primarily products for the treatment of rare diseases.